Monuril Bambini (Fosfomycin Trometamol)

Fosfomycin trometamol penetrates bacterial cells through specific transporters and binds irreversibly to the MurA enzyme, blocking the first step of peptidoglycan synthesis. This prevents cell‑wall formation, leading to bacterial death across a broad range of Gram‑positive and Gram‑negative organisms.

The dose of Monuril Bambini is determined by the prescribing clinician based on the patient’s age, weight, and renal function. No fixed regimen is provided here; the prescriber will select the appropriate single‑dose amount for each individual case.

Safety data for fosfomycin trometamol in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Pregnant or nursing mothers should only use the product if advised by their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monuril Bambini offers a single‑dose oral regimen, which can improve adherence compared with multi‑day courses of trimethoprim‑sulfamethoxazole or nitrofurantoin. Its distinct mechanism targeting MurA provides activity against some resistant strains, though susceptibility testing remains essential to guide therapy.

Store Monuril Bambini at below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use the product if the packaging is damaged or the tablets appear discoloured.

Monuril Bambini is taken orally as a single tablet. The tablet should be swallowed whole with a glass of water, preferably on an empty stomach to maximise absorption. Patients should follow the prescriber’s instructions regarding timing relative to meals.

Serious adverse events include severe allergic reactions such as rash, urticaria or anaphylaxis, Clostridioides difficile‑associated colitis, significant liver enzyme elevation, and acute renal impairment. Any signs of these conditions require immediate medical attention and discontinuation of the drug.

Monuril Bambini should be avoided in patients with known hypersensitivity to fosfomycin or any of its excipients, in those with severe renal impairment where dosing cannot be adjusted, and in individuals with a history of severe allergic reactions to other antibiotics.